Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPIAO for Delayed Platelet Engraftment in Allo-HSCT
NCT01379391Phase 4Unknown
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jun 2010
- Primary completion
- Sep 2015
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 4, open-label trial of recombinant human thrombopoietin in Delayed platelet engraftment (DPE) (2 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Total Response Rate at 4 weeks. Status: unknown.
02
Drugs
recombinant human thrombopoietin
03
Conditions
Delayed platelet engraftment (DPE)
Beyond the preview
Go deeper on NCT01379391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01379391.